Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET plus LAP) versus anastrozole plus trastuzumab (ANA plus TZ) as first-line treatment for postmenopausal women with HER2+and HR+ metastatic breast cancer (MBC) from the UK National Health Service (NHS) perspective

被引：1
|
作者：
Hastings, V.
Delea, T. E.
Amonkar, M.
Lykopoulos, K.
Diaz, J.
Johnston, S. R.
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] GlaxoSmithKline, Collegeville, PA USA
[3] GlaxoSmithKline Global Hlth Outcomes, London, England
[4] GlaxoSmithKline Hllth Outcomes Oncol, London, England
[5] Royal Marsden NHS Fdn Trust, Inst Canc Res, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1035
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
    Janni, Wolfgang
    Alba, Emilio
    Bachelot, Thomas
    Diab, Sami
    Gil-Gil, Miguel
    Beck, Thaddeus J.
    Ryvo, Larisa
    Lopez, Rafael
    Tsai, Michaela
    Esteva, Francisco J.
    Zamora Aunon, Pilar
    Kral, Zdenek
    Ward, Patrick
    Richards, Paul
    Pluard, Timothy J.
    Sutradhar, Santosh
    Miller, Michelle
    Campone, Mario
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (03) : 469 - 479
  • [32] First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
    Wolfgang Janni
    Emilio Alba
    Thomas Bachelot
    Sami Diab
    Miguel Gil-Gil
    Thaddeus J. Beck
    Larisa Ryvo
    Rafael Lopez
    Michaela Tsai
    Francisco J. Esteva
    Pilar Zamora Auñón
    Zdenek Kral
    Patrick Ward
    Paul Richards
    Timothy J. Pluard
    Santosh Sutradhar
    Michelle Miller
    Mario Campone
    Breast Cancer Research and Treatment, 2018, 169 : 469 - 479
  • [33] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Audrey Petitjean
    Jayne Smith-Palmer
    William Valentine
    Bertrand Tehard
    Stephané Roze
    BMC Cancer, 19
  • [34] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
    Petitjean, Audrey
    Smith-Palmer, Jayne
    Valentine, William
    Tehard, Bertrand
    Roze, Stephane
    BMC CANCER, 2019, 19 (1)
  • [35] Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC):: results of a randomised multicentre trial
    Extra, J. M.
    Cognetti, F.
    Maraninch, D.
    Snyder, R.
    Mauriac, L.
    Tubiana-Hulin, M.
    Chan, S.
    Grimes, D.
    Anton, A.
    Marty, M.
    EJC SUPPLEMENTS, 2004, 2 (03): : 125 - 126
  • [36] Cost-effectiveness of letrozole (LET) versus artastrozole (ANA) in postmenopausal women (PMW) with hormone receptor-positive (HR plus ) early-stage breast cancer (EBC) based on indirect comparison of BIG 1-98 and ATAC.
    Delea, T. E.
    Lipsitz, M. A.
    Zelt, S. C.
    Guo, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2-advanced breast cancer-A Chinese healthcare system perspective
    Zhu, Wentao
    Zheng, Miaomiao
    Xia, Panpan
    Hong, Wanglong
    Ma, Guoqiang
    Shen, Aizong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [38] Overall survival (OS) with first-line palbociclib plus letrozole (PAL plus LET) versus placebo plus letrozole (PBO plus LET) in women with estrogen receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2-ABC): Analyses from PALOMA-2.
    Finn, Richard S.
    Rugo, Hope S.
    Dieras, Veronique C.
    Harbeck, Nadia
    Im, Seock-Ah
    Gelmon, Karen A.
    Walshe, Janice Maria
    Martin, Miguel
    Mac Gregor, Mariana Chavez
    Bananis, Eustratios
    Gauthier, Eric Roland
    Lu, Dongrui Ray
    Kim, Sindy
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [39] Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib plus letrozole in postmenopausal patients with advanced HR+/HER2-breast cancer
    O'Shaughnessy, Joyce
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon-Sim
    Sonke, Gabe
    Hart, Lowell
    Campone, Mario
    Petrakova, Katarina
    Winer, Eric P.
    Janni, Wolfgang
    Conte, Pierfranco
    Cameron, David A.
    Andre, Fabrice
    Arteaga, Carlos
    Zarate, Juan Pablo
    Chakravartty, Arunava
    Taran, Tetiana
    Le Gac, Fabienne
    Serra, Paolo
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2022, 82 (04)
  • [40] BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib plus letrozole and on second-line treatment with alpelisib plus fulvestrant
    Allegrini, G.
    Orditura, M.
    Del Mastro, L.
    Zamagni, C.
    Torrisi, R.
    Guarneri, V.
    Paris, I.
    Sarobba, G.
    Puglisi, F.
    Colleoni, M. A.
    Montemurro, F.
    Zambelli, A.
    Cazzaniga, M. E.
    Valerio, M. R.
    Bianchi, G.
    Romagnoli, E.
    Caruso, M.
    Cinieri, S.
    Castelletti, D.
    Arpino, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S302 - S302
12345